Genetically Engineered Extracellular Vesicles Harboring Transmembrane Scaffolds Exhibit Differences in Their Size,...

Area of Science:

• Biotechnology
• Nanomedicine
• Cell Biology

Background:

• Extracellular vesicles (EVs) are promising nanomaterials for drug delivery and therapy.
• Native EVs lack specific targeting and drug-loading capabilities, limiting clinical use.
• Genetic modification of EV membrane scaffolds can introduce desired functions, but impacts are largely unknown.

Purpose of the Study:

• To quantify the effects of genetically engineered membrane scaffolds on EV properties.
• To assess the impact of scaffold integration on EV physicochemical characteristics, molecular profiles, and cell uptake.
• To evaluate different scaffolds including tetraspanins (CD9, CD63, CD81) and VSVG.

Main Methods:

• Utilized gene fusion, molecular imaging, and immuno-based on-chip analysis.
• Examined scaffold integration into EV membranes (endocytic compartment, plasma membrane, or both).
• Analyzed vesicle size, surface marker expression, and recipient cell uptake.

Main Results:

• Scaffold integration increased average EV diameter.
• CD63-GFP reduced CD81 expression; other scaffolds had minimal impact on CD81.
• VSVG-engineered EVs showed significantly higher uptake by recipient cells compared to controls.

Conclusions:

• Incorporating molecular scaffolds alters EV physicochemical properties, surface markers, and cell uptake.
• Scaffold-induced changes must be considered for engineering EVs in targeted therapeutics.
• Engineered EVs offer potential for enhanced therapeutic delivery to diseased cells.